Drug Pricing Alliances Expand In Europe

Slovenia has joined the Valletta group, with Croatia set to follow. Meanwhile, Ireland has formally signaled its interest in joining the BeNeLuxA collaboration.

Gold coins
European Alliances For Securing Better Access To Expensive Treatments Are Expanding

European inter-country pricing alliances are again expanding as EU member states grapple with the problem of how to pay for expensive treatments. Ireland has announced its formal interest in joining the BeNeLuxA initiative, while Slovenia has joined the Valleta group, with Croatia, and possibly France to follow.

Last year, Spain, Italy, Portugal, Greece, Malta, Cyprus, Ireland and Romania all signed up to the Valletta Declaration. The shared...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Government Payers

CMS Should ‘Clarify’ That Part B Inflation Rebates Do Not Apply In Medicare Advantage, Pharma Urges

The Centers for Medicare and Medicaid Services is considering imposing price inflation rebates on Part B drugs furnished to enrollees in Medicare Advantage plans in addition to those covered by fee-for-service Medicare.

PS-MarketAccess (Premium-2): Why Financial Scammers Are So Successful Targeting Doctors

 
• By 

Doctors are increasingly falling victim to financial scams due to their high incomes, busy schedules, and trust in professional networks. Recognizing the tactics scammers use and the reasons behind physicians’ susceptibility is essential for protecting medical professionals.

PBM Legislation: Medicare Rebate Reform May Be Challenging Amid Disruption From Redesign

 
• By 

US lawmakers will undoubtedly continue to work on pharmacy benefit manager reform legislation in 2025, given its bipartisan support. But policies impacting rebates that could lead to higher premiums in Part D may be a tough sell in the midst of the benefit redesign.

Accelerated Approvals In Medicare: CED Guidance Notes Ongoing Concern With Surrogate Endpoints

 
• By 

Medicare coverage with evidence development final guidance includes few substantive changes from the proposed version despite biopharma stakeholder concerns.

More from Market Access

analysis

Shot Across The Bow? Express Scripts Lawsuit Seeks To Derail Fall-Out From FTC PBM Report

 
• By 

Pharmacy benefit manager sues Federal Trade Commission claiming chair Khan has orchestrated a campaign against PBMs that is not based in fact.

‘Alternative' PBMs Say Vertical Integration Unfairly Carving Them Out Of The Game

 

Alternatives to the top pharmacy benefits managers argue health plan-PBM integration is leading to anti-competitive tactics that make it impossible for some employers to switch PBMs.

UK MHRA First-Half New Drug Approvals Show Overwhelming Use Of EU Reliance Procedures

 
• By 

The UK regulator approved 16 medicines containing a new active substance in the first half of this year, while the European Commission issued marketing authorizations for 20 NAS-containing drugs.